Literature DB >> 21543162

Proton beam therapy for hepatocellular carcinoma located adjacent to the alimentary tract.

Hidetsugu Nakayama1, Shinji Sugahara, Kuniaki Fukuda, Masato Abei, Junichi Shoda, Hideyuki Sakurai, Koji Tsuboi, Yasushi Matsuzaki, Koichi Tokuuye.   

Abstract

PURPOSE: To evaluate the safety and effectiveness of proton beam therapy for hepatocellular carcinoma (HCC) located adjacent to the alimentary tract. PATIENTS AND METHODS: Forty-seven patients (median age, 69 years; range, 43-82 years) who had HCC located within 2 cm of the alimentary tract underwent proton beam therapy. Liver damage according to the Child-Pugh classification was Class A in 35 patients, Class B in 9, and Class C in 3. Treatment protocols of the early 16 patients and the late 31 patients were 72.6 GyE in 22 fractions and 77 GyE in 35 fractions, respectively.
RESULTS: During the median follow-up period of 23 months, 24 patients died; the remaining 23 patients were alive until September 2008. The median overall survival was 33.9 months (95% confidence interval [CI], 10.8-57.0 months). Actuarial overall and local progression-free survival rates at 3 years were 50.0% and 88.1%, respectively. Grade 2 and 3 alimentary tract hemorrhage was observed in 3 (6.4%) and 1 (2.1%) patients, respectively.
CONCLUSIONS: Our proton beam therapy strategy for HCC located adjacent to the alimentary tract seems to be effective but should be performed with caution.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21543162     DOI: 10.1016/j.ijrobp.2010.03.015

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  21 in total

Review 1.  Clinical evidence of particle beam therapy (proton).

Authors:  Takashi Ogino
Journal:  Int J Clin Oncol       Date:  2012-03-17       Impact factor: 3.402

2.  Proton therapy for hepatocellular carcinoma.

Authors:  Ted C Ling; Joseph I Kang; David A Bush; Jerry D Slater; Gary Y Yang
Journal:  Chin J Cancer Res       Date:  2012-12       Impact factor: 5.087

Review 3.  Proton therapy for hepatocellular carcinoma: Current knowledges and future perspectives.

Authors:  Gyu Sang Yoo; Jeong Il Yu; Hee Chul Park
Journal:  World J Gastroenterol       Date:  2018-07-28       Impact factor: 5.742

Review 4.  Proton Beam Therapy for Hepatocellular Carcinoma: A Review of the University of Tsukuba Experience.

Authors:  Masashi Mizumoto; Yoshiko Oshiro; Toshiyuki Okumura; Nobuyoshi Fukumitsu; Haruko Numajiri; Kayoko Ohnishi; Teruhito Aihara; Hitoshi Ishikawa; Koji Tsuboi; Hideyuki Sakurai
Journal:  Int J Part Ther       Date:  2016-03-24

Review 5.  Radiotherapy as valid modality for hepatocellular carcinoma with portal vein tumor thrombosis.

Authors:  Jeong Il Yu; Hee Chul Park
Journal:  World J Gastroenterol       Date:  2016-08-14       Impact factor: 5.742

6.  A systematic review of publications on charged particle therapy for hepatocellular carcinoma.

Authors:  Hiroshi Igaki; Masashi Mizumoto; Toshiyuki Okumura; Kiyoshi Hasegawa; Norihiro Kokudo; Hideyuki Sakurai
Journal:  Int J Clin Oncol       Date:  2017-09-04       Impact factor: 3.402

Review 7.  Proton Therapy in the Management of Hepatocellular Carcinoma.

Authors:  Jana M Kobeissi; Lara Hilal; Charles B Simone; Haibo Lin; Christopher H Crane; Carla Hajj
Journal:  Cancers (Basel)       Date:  2022-06-12       Impact factor: 6.575

8.  Clinical outcomes and toxicities of proton radiotherapy for gastrointestinal neoplasms: a systematic review.

Authors:  Vivek Verma; Steven H Lin; Charles B Simone; Minesh P Mehta
Journal:  J Gastrointest Oncol       Date:  2016-08

Review 9.  Role of modern radiotherapy in managing patients with hepatocellular carcinoma.

Authors:  Liang-Cheng Chen; Hon-Yi Lin; Shih-Kai Hung; Wen-Yen Chiou; Moon-Sing Lee
Journal:  World J Gastroenterol       Date:  2021-05-28       Impact factor: 5.742

Review 10.  Who Will Benefit from Charged-Particle Therapy?

Authors:  Kyung Su Kim; Hong-Gyun Wu
Journal:  Cancer Res Treat       Date:  2021-06-21       Impact factor: 4.679

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.